NCT05152212View on ClinicalTrials.gov

Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions
Cancer
Interventions
BIOLOGICAL

LVGN7409

Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.

Trial Locations (1)

100021

Center Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Lyvgen Biopharma Holdings Limited

INDUSTRY

NCT05152212 - Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy | Biotech Hunter | Biotech Hunter